文献速递间质性肺疾病

成人间质性肺疾病Ⅱ/Ⅲ期药物随机对照试验的地理分布

Geographical Distribution of Phase II/III Pharmaceutical Randomized Controlled Trials in Adults With Interstitial Lung Disease.
PubMed 文献 · Chest · 2025-08-14

该研究检索ClinicalTrials.gov截至2024年2月的Ⅱ/Ⅲ期平行组药物随机对照试验,共纳入168项,发现北美参与最多(70%),欧洲52%、亚洲42%;试验数量随医疗可及性与质量指数升高而增加,Ⅲ期试验数量与城市人口比例正相关。全球参与扩大但不均衡,非洲仅8%。

要点

  • 间质性肺疾病药物RCT集中于北美和欧洲,非洲参与最少。
  • Ⅱ/Ⅲ期RCT数量与医疗可及性与质量指数正相关。
  • Ⅲ期RCT数量及招募站点数与城市人口比例正相关。

核心结论

  • 尽管全球参与扩大,间质性肺疾病药物RCT活动仍集中在北美和欧洲,地区间地理差异显著。

研究设计与样本

  • 检索ClinicalTrials.gov自建库至2024年2月的Ⅱ/Ⅲ期平行组药物随机对照试验,共纳入168项。
  • 试验详情与招募站点被提取,并与各国间质性肺疾病年龄标化患病率、医疗可及性与质量指数、社会人口指数及城市人口比例进行关联分析。

主要发现

  • 168项试验中65%为Ⅱ期、35%为Ⅲ期,40%自2020年起启动。
  • 北美参与70%的试验,欧洲52%、亚洲42%、大洋洲28%、南美洲20%、非洲8%。
  • 过去20年亚洲、南美洲和澳大利亚参与增加,但印度、日本、俄罗斯和英国近期下降。
  • 非洲多数招募站点参与Ⅱ期试验,亚洲和南美洲多数参与Ⅲ期试验。
  • 一国Ⅱ/Ⅲ期试验数量与医疗可及性与质量指数正相关;Ⅲ期试验数量及招募站点数与城市人口比例正相关。

临床怎么用

  • 解读间质性肺疾病RCT结果时需考虑全球地理分布不均衡对代表性的影响。
  • 在资源有限地区推广RCT证据需结合当地医疗可及性与城市化水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmaceutical randomized controlled trials (RCTs) are critical for advancing treatments in interstitial lung disease (ILD). This study evaluated the global distribution of pharmaceutical RCTs of ILD and their associations with country-specific features. RESEARCH QUESTION: Do ILD RCT activities relate to disease prevalence, health care quality, sociodemographic status, and urban population size? STUDY DESIGN AND METHODS: ClinicalTrials.gov was searched from inception to February 2024 for phase II and phase III parallel-group pharmaceutical RCTs of ILD. Trial details and recruiting sites were extracted. For evaluation of relationships with trial activities, country-specific age-standardized prevalence rates for ILD, the Healthcare Access and Quality Index, and the Socio-Demographic Index were obtained from the Global Burden of Disease databases, and urban population percentages were obtained from the World Bank. RESULTS: A total of 168 RCTs were identified (65% phase II and 35% phase III), which increased over time, with 40% having commenced since 2020. North America participated in the most RCTs (70%), followed by Europe (52%), Asia (42%), Oceania (28%), South America (20%), and Africa (8%). Over the past 2 decades, there was increased participation in ILD RCTs in Asia, South America, and Australia, although recent declines were noted in India, Japan, Russia, and the United Kingdom. The majority of recruiting sites in Africa participated in phase II trials, while most in Asia and South America were involved in phase III trials. For a given country, the numbers of phase II and phase III RCTs conducted were positively associated with the Healthcare Access and Quality Index; the numbers of phase III RCTs conducted and recruiting sites were positively associated with urban population percentages. INTERPRETATION: Despite expanding global involvement, ILD RCT activities remain concentrated in North America and Europe, with substantial geographical disparity across different regions. Given the increasing ILD disease burden in many countries, ongoing efforts are needed to enhance representativeness of RCT findings and promote their adoption into clinical care.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Guan M, Marshall E, Sughesh S, et al. Geographical Distribution of Phase II/III Pharmaceutical Randomized Controlled Trials in Adults With Interstitial Lung Disease. Chest. 2025. PMID: 40818774. doi:10.1016/j.chest.2025.07.4078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。